Matching articles for "Focalin"
Issue 1736 · September 1, 2025
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD…

Med Lett Drugs Ther. 2025 Sep 1; 67(1736):137-44 doi:10.58347/tml.2025.1736a
Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD has been associated with reduced risks of substance abuse, criminal behavior, unintentional injuries, serious traffic accidents, and all-cause mortality. Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Issue 1664 · November 28, 2022 Free
In Brief: Alternatives to Adderall

The short-acting formulation of mixed amphetamine salts ( Adderall , and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply in…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):191-2
The short-acting formulation of mixed amphetamine salts ( Adderall , and generics) FDA-approved for treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy, is currently in short supply in the US. Until an adequate supply is restored, patients may be looking for alternatives.
Issue 1634 · October 4, 2021
Azstarys (Serdexmethylphenidate/Dexmethylphenidate) for ADHD

The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate ( Azstarys – Corium) for once-daily treatment of…

Med Lett Drugs Ther. 2021 Oct 4; 63(1634):157-9
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate ( Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Azstarys is the first product containing serdexmethylphenidate to become available in the US.
Issue 1590 · January 27, 2020
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in…

Med Lett Drugs Ther. 2020 Jan 27; 62(1590):9-15
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurodevelopmental disorder that has been diagnosed in up to 10% of school-age children in the US and frequently persists into adulthood. A study in a large Danish cohort found that ADHD was associated with higher mortality rates in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD in children has been reported to decrease the risk of substance abuse in adolescents, and use of ADHD medications in adults has been associated with a reduced risk of serious traffic accidents and criminal behavior.4-6 Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
Issue 1578 · August 12, 2019
Jornay PM - Evening-Dosed Methylphenidate for ADHD

The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit…

Med Lett Drugs Ther. 2019 Aug 12; 61(1578):126-8
The FDA has approved Jornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients >6 years old. Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning.
Issue 1533 · November 6, 2017
Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD

The FDA has approved an extended-release orally disintegrating tablet formulation of methylphenidate ( Cotempla XR-ODT – Neos Therapeutics) for once-daily treatment of attention-defi cit/hyperactivity…

Med Lett Drugs Ther. 2017 Nov 6; 59(1533):183-5
The FDA has approved an extended-release orally disintegrating tablet formulation of methylphenidate ( Cotempla XR-ODT – Neos Therapeutics) for once-daily treatment of attention-defi cit/hyperactivity disorder (ADHD) in children 6-17 years old. Cotempla XR-ODT is the first extended-release orally disintegrating tablet formulation of methylphenidate to become available in the US.
Issue 1495 · May 23, 2016
QuilliChew ER - Extended-Release Chewable Methylphenidate Tablets

The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate ( QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first…

Med Lett Drugs Ther. 2016 May 23; 58(1495):68-9
The FDA has approved a once-daily, extended-release chewable tablet formulation of methylphenidate ( QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first long-acting chewable formulation of the drug to be marketed in the US. Immediate-release chewable methylphenidate tablets ( Methylin , and generics) have been available since 2003.
Issue 1464 · March 16, 2015
Drugs for ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into…

Med Lett Drugs Ther. 2015 Mar 16; 57(1464):37-40
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into adulthood. A recent study in a large Danish cohort found that ADHD was associated with increased mortality in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD has been reported to lower the risk of serious traffic accidents and criminal behavior.
Issue 1409 · February 4, 2013
Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate

The FDA has approved a once-daily, extended-release oral suspension of methylphenidate ( Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid…

Med Lett Drugs Ther. 2013 Feb 4; 55(1409):10-1
The FDA has approved a once-daily, extended-release oral suspension of methylphenidate ( Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid formulation of the drug to be marketed for once-daily use. A short-acting oral solution ( Methylin , and generics) has been available since 2003.
Issue 105 · May 1, 2011
Drugs for Treatment of ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.

Treat Guidel Med Lett. 2011 May; 9(105):23-8
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.
Issue 1308 · March 23, 2009
Focalin XR for ADHD

Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children…

Med Lett Drugs Ther. 2009 Mar 23; 51(1308):22-4
Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing.
Issue 51 · November 1, 2006
Drugs for Treatment of ADHD

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by…

Treat Guidel Med Lett. 2006 Nov; 4(51):77-82
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by a persistent pattern of frequent, severe inattention and/or hyperactivity/impulsivity that starts before the age of 7, is present in 2 or more settings (such as home and school), causes significant impairment in function, and is not caused by another mental disorder. The drugs approved for treatment of ADHD by the FDA are listed in this article. Except for atomoxetine, they are all stimulants and are classified as controlled substances by the US Drug Enforcement Administration (DEA).
Issue 1159 · June 23, 2003
Prilosec, Nexium and Stereoisomers

Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram…

Med Lett Drugs Ther. 2003 Jun 23; 45(1159):51-2
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram (Lexapro) and dexmethylphenidate
Issue 1149 · February 3, 2003
Atomoxetine (Strattera) for ADHD

Atomoxetine ( Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is…

Med Lett Drugs Ther. 2003 Feb 3; 45(1149):11-2
Atomoxetine ( Strattera - Lilly) is the first non-stimulant drug to be approved by the FDA for treatment of attention deficit hyperactivity disorder (ADHD). Unlike other drugs approved for use in ADHD, it is not a controlled substance and is approved for use in adults as well as children. Older non-stimulant drugs that have been used to treat ADHD, although not FDA-approved, include the alpha 2 -agonist clonidine ( Catapres , and others) and the tricyclic antidepressant desipramine ( Norpramin , and others) (Medical Letter 1996; 38:109).
Issue 1130 · May 13, 2002
Dexmethylphenidate (Focalin) For ADHD

Dexmethylphenidate ( Focalin - Novartis), a new formulation of methylphenidate ( Ritalin , and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is…

Med Lett Drugs Ther. 2002 May 13; 44(1130):45-6
Dexmethylphenidate ( Focalin - Novartis), a new formulation of methylphenidate ( Ritalin , and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is the d-threo-enantiomer of racemic methylphenidate. "Now the right half may be all your patients need," said a recent ad. Focalin is the third new methylphenidate formulation marketed in the last two years.